Canine Giant Hypertrophic Gastritis Treated Successfully with Partial Gastrectomy

2014 ◽  
Vol 50 (1) ◽  
pp. 62-66 ◽  
Author(s):  
Denty P. Vaughn ◽  
Jason Syrcle ◽  
Jim Cooley
Keyword(s):  
Weight Loss ◽  
Treatment Success ◽  
Clinical Signs ◽  
Partial Gastrectomy ◽  
Surgical Excision ◽  
Term Treatment ◽  
Gastric Body ◽  
Hypertrophic Gastritis ◽  
Clinically Normal ◽  
Long Term Treatment

A 4 yr old castrated male Jack Russell terrier was presented with a 2 mo history of vomiting, anorexia, and weight loss. Abdominal radiographs and ultrasound supported the diagnosis of gastric outflow obstruction. Celiotomy and gastrotomy revealed a large, narrowly based mass originating from the mucosa of the dorsal gastric body, occupying the lumen of the stomach and protruding through the pylorus into the duodenum. A partial gastrectomy was performed to excise the mass along with a 1 cm margin of grossly normal tissue. Giant hypertrophic gastritis was diagnosed via histopathology of the excised tissue. Giant hypertrophic gastritis is a rarely diagnosed disease of canines, characterized by giant gastric folds, hypoalbuminemia, and mucosal hypertrophy. Long-term treatment success has not been previously reported. In the case described herein, surgical excision of the affected gastric tissue provided complete resolution of clinical signs. Twelve mo following surgery, no recurrence of either vomiting or weight loss had been noted and the dog was clinically normal.

scholarly journals Long‐term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss

Obesity ◽  
2013 ◽  
Vol 21 (10) ◽  
pp. 1975-1981 ◽  
Author(s):  
Farid Saad ◽  
Ahmad Haider ◽  
Gheorghe Doros ◽  
Abdulmaged Traish
Keyword(s):  
Weight Loss ◽  
Term Treatment ◽  
Sustained Weight Loss ◽  
Long Term Treatment

scholarly journals Interaction of race with weight loss and resolution of obesity co-morbidities in patients undergoing laparoscopic roux-en-y gastric bypass (lrygb): an analysis of 83,059 bold database patients00000000000

2021 ◽  
Vol 11 (3) ◽  
pp. 76-84
Author(s):  
Jeffrey S Emrich ◽  
Casey G Sheck ◽  
Leon Kushnir ◽  
Cristina Nituica ◽  
Gus J Slotman
Keyword(s):  
Weight Loss ◽  
African American ◽  
African Americans ◽  
Racial Differences ◽  
Term Treatment ◽  
Medical Problems ◽  
Obstructive Sleep ◽  
Co Morbidity ◽  
Long Term Treatment ◽  
Racial Variations

Background: Previous studies identified differences by race in the distribution of medical problems associated with morbid obesity. Whether or not outcomes after LRYGB also vary by race is unknown. Objective: To identify racial variations in weight loss and resolution of obesity co-morbidities after LRYGB. Methods: Data from 83,059 BOLD database LRYGB patients was analyzed retrospectively in five groups: African-American (n=9,055), Caucasian (n=63,352), Hispanic (n=6,893), Asian (n=198), and Other (n=3,561). Results: Weight and BMI were higher in African-Americans versus Caucasians, Hispanics, Other (12 months, p<0.0001). Hypertension persisted increased among African-Americans versus Caucasians, Hispanics, Other through 24 months (p<0.01). Caucasian cholelithiasis (18 months, p<0.05), abdominal panniculitis (12 months, p<0.01,) and depression (24 months, p<0.05) continued higher than other races. GERD was highest in African-Americans and Caucasians. Dyslipidemia affected Caucasians, African-Americans, and Other most (12 months, p<0.05). Hispanic depression was lowest (24 months, p<0.05). Other had highest stress urinary incontinence (12 months, p<0.05). Racial differences in diabetes, liver disease, obstructive sleep apnea, obesity hypoventilation syndrome, gout, back and musculoskeletal pain, leg edema, alcohol use, and non-depression psychological issues were not significant beyond 6 months. Resolution of angina, CHF, pulmonary hypertension, and polycystic ovarian disease did not vary by race. Conclusions: LRYGB improves obesity weight and co-morbidity outcomes overall, but long-term treatment effects vary by race. African-American weight and hypertension, and African-American/Caucasian GERD, and dyslipidemia resolve least. Caucasian abdominal issues and depression dominate. Racial variations in many obesity co-morbidities disappear by 12 months post-operatively.

Focal myasthenia gravis as a paraneoplastic syndrome of canine thymoma: improvement following thymectomy

1996 ◽  
Vol 32 (2) ◽  
pp. 111-117 ◽  
Author(s):  
MF Lainesse ◽  
SM Taylor ◽  
SL Myers ◽  
D Haines ◽  
JD Fowler
Keyword(s):  
Weight Loss ◽  
Myasthenia Gravis ◽  
Acetylcholine Receptor ◽  
Paraneoplastic Syndrome ◽  
Mediastinal Mass ◽  
Clinical Signs ◽  
Diagnostic Evaluation ◽  
Antibody Concentration ◽  
Surgical Removal ◽  
Clinically Normal

A 10-year-old, neutered male cocker spaniel-cross experienced regurgitation, dry retching, and weight loss. A large, mediastinal mass and dilatation of the esophagus were seen on thoracic radiographs. Cytological, histopathological, immunohistochemical, and serological findings were consistent with a lymphoepithelial thymoma and focal, esophageal myasthenia gravis. Surgical removal of the mass resulted in rapid resolution of the megaesophagus and a decrease in serum acetylcholine-receptor antibody concentration. The dog was clinically normal until the thymoma recurred six months postoperatively. Clinical signs, diagnostic evaluation, management, and treatment of a dog with thymoma and megaesophagus are described.

Arthroscopic treatment of fragmented coronoid process with severe elbow incongruity

2013 ◽  
Vol 26 (01) ◽  
pp. 27-33 ◽  
Author(s):  
E. de Bakker ◽  
D. Van Vynckt ◽  
E. Coppieters ◽  
H. van Bree ◽  
B. Van Ryssen ◽  
...  
Keyword(s):  
Clinical Signs ◽  
Case Series ◽  
Term Treatment ◽  
Coronoid Process ◽  
Heavy Exercise ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Long Term Treatment

SummaryThe purpose of this study was to investigate the long-term treatment results of fragmented coronoid process (FCP) in joints with a radio-ulnar step greater than 3 mm. Treatment of these patients only consisted of fragment removal, without correction of the incongruity.The eight Bernese Mountain Dogs (11 joints) included in this study showed obvious clinical signs of elbow disease and were diagnosed with severe elbow incongruity and concomitant FCP in the time period from 1999–2003. At that time, elbow radiography, computed tomography, and arthroscopy were performed. The mean follow-up period was 5.6 years. The follow-up consisted of a telephone questionnaire combined with a clinical and radiographic re-evaluation at our clinic.The questionnaire revealed that all dogs were either free of lameness or only lame following heavy exercise. One dog sporadically required medication after heavy exercise. The owner satisfaction rate was 100%. The clinical re-evaluation did not reveal any signs of pain or lameness in all cases. Range-of- motion was decreased in nine of the 11 elbows. Radiographs revealed an increase in severity of osteoarthritis in every case.In this case series, arthroscopic fragment removal without treatment of incongruity was demonstrated to be a valuable treatment option and may provide a satisfactory long-term outcome.

scholarly journals Attenuation of Weight Loss Through Improved Antilipolytic Effect in Adipose Tissue Via the SGLT2 Inhibitor Tofogliflozin

2019 ◽  
Vol 104 (9) ◽  
pp. 3647-3660 ◽  
Author(s):  
Akihiro Yoshida ◽  
Yasuhiro Matsubayashi ◽  
Toshiaki Nojima ◽  
Hideki Suganami ◽  
Takahiro Abe ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Weight Loss ◽  
Adipose Tissue ◽  
Glycosylated Hemoglobin ◽  
Term Treatment ◽  
Integrated Analysis ◽  
Long Term Treatment ◽  
Urinary Glucose

Abstract Context Although calorie loss from increased urinary glucose excretion continues after long-term treatment with sodium-glucose cotransporter 2 inhibitors (SGLT2is), the mechanisms of the attenuated weight loss due to SGLT2is are not well known. Objective To examine the mechanism of the attenuated weight loss during long-term treatment with an SGLT2i, tofogliflozin, focusing on the antilipolytic effect of insulin on adipose tissue. Design and Participants An integrated analysis was performed using data from two phase 3 studies of 52 weeks of tofogliflozin administration. The antilipolytic effect was evaluated using adipose tissue insulin resistance (Adipo-IR) calculated from the product of the levels of fasting insulin (f-IRI) and fasting free fatty acids (f-FFAs). Results Data from 774 patients with type 2 diabetes (mean age, 58.5 years; glycosylated hemoglobin, 8.1%; body mass index, 25.6 kg/m2; estimated glomerular filtration rate, 83.9 mL/min/1.73m2; 66% men) were analyzed. Weight loss plateaued between weeks 24 and 52 after decreasing significantly. f-IRI levels decreased significantly from baseline to week 24, and the decrease was maintained until Week 52. f-FFA levels significantly increased, peaked at week 24, then declined from weeks 24 to 52. Adipo-IR levels declined progressively throughout the 52 weeks (−3.6 mmol/L·pmol/L and −6.2 mmol/L·pmol/L at weeks 24 and 52, respectively; P < 0.001 baseline vs weeks 24 and 52 and week 24 vs week 52). Higher baseline Adipo-IR levels were independently associated with greater weight loss at week 52. Conclusion The improved antilipolytic effect in adipose tissue may attenuate progressive lipolysis, leading to attenuating future weight loss induced by an SGLT2i in patients with type 2 diabetes.

Sign in / Sign up

Export Citation Format

Share Document